It was a busy week for Australia’s top brokers. This has led to a number of broker notes being released.

Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think these ASX shares are in the buy zone:

Hub24 Ltd (ASX: HUB)

According to a note out of Bell Potter, its analysts have retained their buy rating and $110.00 price target on this investment platform provider’s shares. The broker highlights that despite early weakness, global equity markets recovered and posted outsized returns for the June quarter. In light of this, Bell Potter has upgraded its model to reflect strong positive mark-to-markets. Outside this, the broker believes that a heavy decline since its November peak, despite earnings upgrades and further positive adjustments yet to flow through, has created a buying opportunity for investors. The Hub24 share price ended the week at $81.04.

Northern Star Resources Ltd (ASX: NST)

A note out of Citi reveals that its analysts have retained their buy rating and $29.70 price target on this gold miner’s shares. The broker was pleased with Northern Star’s quarterly update, which revealed gold sales comfortably ahead of expectations during the fourth quarter. It notes that this helped take Northern Star’s gold sales beyond its revised guidance for FY 2026. As a result of this strong performance, Citi continues to see plenty of value in the company’s shares at current levels. The Northern Star share price was fetching $22.16 at Friday’s close.

ResMed Inc. (ASX: RMD)

Analysts at Morgans have retained their buy rating and $41.72 price target on this sleep disorder treatment company’s shares. According to the note, the broker highlights that ResMed’s shares have de-rated to just 16 times forward earnings. This is its lowest valuation in over a decade and comes despite the market continuing to forecast double-digit earnings per share growth. And while there are risks from GLP-1 therapies, an oral OSA therapy, and the potential re-entry of a key competitor next year, Morgans points out that current industry data and its operating performance provide limited evidence of a material deterioration in underlying demand. The ResMed share price ended the week at $30.50.

The post Top brokers name 3 ASX shares to buy next week appeared first on The Motley Fool Australia.

More reading

• Healthcare shares lead the ASX 200 again as sector rotation gathers pace
• Buy, hold, sell: Objective Corp, ResMed, and South32 shares
• 9 ASX 200 shares with renewed buy ratings for FY27
• 10 of the best ASX shares to buy in FY 2027
• Here are the top 10 ASX 200 shares today

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24 and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Hub24. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX 200 healthcare shares led the 11 market sectors last week with a 5.64% gain over the five trading days.

The S&P/ASX 200 Index (ASX: XJO) lifted 0.92% in the final trading week of FY26. 

The ASX 200 finished the week at 8,844.4 points.

This is the second time in three weeks that ASX 200 healthcare shares have been out in front. 

A sector rotation appears underway as value investors swoop on blue-chip favourites like CSL Ltd (ASX: CSL) and Pro Medicus Ltd (ASX: PME). 

The healthcare sector appears to have turned on 3 June when the S&P/ASX 200 Health Care Index (ASX: XHJ) hit a 9-year low.

That represented a 39% decline over 12 months. You can read comprehensive analysis of why the healthcare sector struggled in FY26 here.

Since then, healthcare shares have increased 20% in just one month compared to an 0.7% rise for the ASX 200 overall. 

In a new note, top broker UBS said ASX 200 healthcare shares and US biotech stocks both rose strongly in June, commenting:

There was limited company specific news to explain this recovery, suggesting it was due to broader market forces including sector rotation.

Healthcare was the worst performer among the 11 market sectors in FY26. You can read more about the market’s winners and losers in FY26 here. 

Now, let’s review some individual stock performances from last week.

Healthcare shares led the ASX sectors last week

The CSL share price rose 6.05% to $121.81 last week, and it’s up 32% since 3 June. 

Pro Medicus shares jumped 11% to $209.65 on Friday, and are up 31% since 3 June. 

Resmed CDI (ASX: RMD) shares ascended 5.39% to $30.50 last week, and are 18% higher since 3 June. 

Sonic Healthcare Ltd (ASX: SHL) shares rose 4.06% to $21.25 last week, and are up 13.1% over the month. 

The Ramsay Health Care Ltd (ASX: RHC) share price lifted 2.46% to $44.16 last week, and is up 21% since 3 June. 

The Cochlear Ltd (ASX: COH) share price increased 5.87% to $124.96 last week, and is up 31% since 3 June. 

Telix Pharmaceuticals Ltd (ASX: TLX) shares ripped 10.11% to $16.88 on Friday, and are up 38% over the month.

Respiratory imaging technology company 4DMedical Ltd (ASX: 4DX) rose 2.16% to $4.25 per share on Friday. 

4DMedical shares are up 12% since 3 June. 

The ASX 200 healthcare share was the best performer of the entire ASX 200 in FY26 after skyrocketing 1,786%. 

ASX 200 market sector snapshot

Here’s how the 11 market sectors stacked up last week, according to CommSec data.

Over the five trading days:

S&P/ASX 200 market sector	Change last week
Healthcare (ASX: XHJ)	5.64%
Information Technology (ASX: XIJ)	2.42%
Materials (ASX: XMJ)	2.08%
Financials (ASX: XFJ)	1.74%
Energy (ASX: XEJ)	0.74%
Communication (ASX: XTJ)	(0.91%)
Industrials (ASX: XNJ)	(1.04%)
Consumer Discretionary (ASX: XDJ)	(1.31%)
Consumer Staples (ASX: XSJ)	(1.68%)
A-REIT (ASX: XPJ)	(3.7%)
Utilities (ASX: XUJ)	(5.78%)

 

The post Healthcare shares lead the ASX 200 again as sector rotation gathers pace appeared first on The Motley Fool Australia.

More reading

• 3 ASX shares down at least 50% in FY26
• Top brokers name 3 ASX shares to buy next week
• Buy, hold, sell: Objective Corp, ResMed, and South32 shares
• How much do I need in superannuation to receive $5,500 per month in passive income?
• 10 of the best ASX shares to buy in FY 2027

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL, Cochlear, Pro Medicus, Sonic Healthcare, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

After a record-breaking year, S&P/ASX 200 Index (ASX: XJO) lithium stocks had a month to forget in June.

From market close on 29 May through to the closing bell on 30 June, the ASX 200 gained 0.5%.

Here’s how these ASX 200 lithium stocks performed over the month just past:

• Mineral Resources Ltd (ASX: MIN) shares tumbled 15.5% to close June at $62.07 apiece
• Liontown Resources Ltd (ASX: LTR) shares fell 30.2% to close June at $1.69 apiece
• PLS Group Ltd (ASX: PLS) – formerly Pilbara Minerals – shares dropped 22.3% to close June at $5.02 each
• IGO Ltd (ASX: IGO) shares tumbled 23.1% to close June at $7.37 apiece

What sent ASX 200 lithium stocks crashing lower?

The common headwind pressuring all the big Aussie lithium producers was a sharp pullback in spodumene (a lithium-bearing ore) prices. Spodumene prices fell around 12% in June, according to data from Trading Economics.

Though it’s important to note that the spodumene price remains up around 160% over past 12 months, which also still sees the ASX 200 lithium stocks racing ahead of the 1.5% one-year gains posted by the benchmark index.

Here’s what I mean (price data below through to 2 July):

• Mineral Resources shares are up 183.9% in 12 months
• Liontown shares are up 143.9% in 12 months
• PLS shares are up 273.0% in 12 months
• IGO shares are up 80.4% in 12 months

Which helps put the June retrace into some perspective!

What else moved the Aussie miners in June?

PLS shares closed down 4.7% on 19 June after the ASX 200 lithium stock reported that it had approved up to $175 million of spending ahead of the final investment decision (FID) at its P2000 Project, within its Pilgangoora hard-rock lithium operation.

The miner is studying the potential to increase Pilgangoora’s concentrate production capacity to around 2 million tonnes a year.

PLS CEO Dale Henders noted:

P2000 has the potential to represent the next major phase of growth at Pilgangoora and further strengthen PLS’ position as one of the world’s leading lithium producers. This pre-FID capital expenditure preserves optionality and maintains momentum along the critical path.

By progressing long-lead procurement, engineering and early works now, we are positioning PLS to respond to future lithium demand while retaining optionality for the timing of any final investment decision.

Mineral Resources was the only other ASX 200 lithium stock to release major news in June.

Mineral Resources shares closed down 2.5% on 25 June after the diversified miner announced that its Western Australia-based Lucky Bay Garnet Project would enter care and maintenance commencing on 1 July.

The company said it expects to book a non-cash impairment on the written down value of Lucky Bay of around $40 million for FY 2026.

The post Why did ASX 200 lithium stocks like PLS, Liontown and Mineral Resources shares get smashed in June? appeared first on The Motley Fool Australia.

More reading

• 9 ASX 200 shares with renewed buy ratings for FY27
• 5 best ASX 200 mining shares of FY26
• ASX shares vs. property in FY26: Which investment outperformed?
• 6 ASX 200 large-cap shares that rose 60% to 275% in FY26
• The ASX 200 sector that outperformed the benchmark 7 to 1 in FY26. Can it keep delivering?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.